Complications of <scp>immuno‐oncology</scp> care: what urologist should know
Valentina Grajales(The University of Texas MD Anderson Cancer Center), Neal D. Shore(Carolina Urologic Research Center), Alberto Martini(The University of Texas MD Anderson Cancer Center)
Cited by 2
Related Papers
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
|New England Journal of Medicine|2020|442